Low-density lipoprotein-independent effects of statins

被引:199
作者
Davignon, J
Laaksonen, R
机构
[1] Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
[2] Univ Helsinki, Dept Clin Pharmacol, FIN-00014 Helsinki, Finland
关键词
D O I
10.1097/00041433-199912000-00010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Statins have pleiotropic properties that complement their cholesterol-lowering effects. These properties may partly account for their established benefit in the prevention of coronary artery disease beyond the reduction of LDL-cholesterol levels. The most widely recognized properties are reviewed here. They include: (i) nitric oxide-mediated improvement of endothelial dysfunction and upregulation of endothelin-1 expression; (ii) antioxidant effects; (iii) anti-inflammatory properties; (iv) inhibition of cell proliferation with anticarcinogenic actions in animals; (v) stabilization of atherosclerotic plaques; (vi) anticoagulant effects; and (vii) inhibition of graft rejection after heart and kidney transplantation. As advances are made in our knowledge, new properties are steadily being uncovered. Pleiotropic effects are currently being given consideration when instituting combination therapy for patients at high cardiovascular risk. Some pleiotropic effects are negative, and may account for occasional untoward drug interactions. For many of these new properties, the clinical relevance has not been established. The challenge for the future will be to design and carry out appropriate clinical trials to establish their relative importance in the prevention of coronary artery disease. Curr Opin Lipidol 10:543-559, (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:543 / 559
页数:17
相关论文
共 137 条
  • [11] LOVASTATIN INHIBITS LOW-DENSITY-LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES - INVITRO AND INVIVO STUDIES
    AVIRAM, M
    DANKNER, G
    COGAN, U
    HOCHGRAF, E
    BROOK, JG
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (03): : 229 - 235
  • [12] Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis
    Baller, D
    Notohamiprodjo, G
    Gleichmann, U
    Holzinger, J
    Weise, R
    Lehmann, J
    [J]. CIRCULATION, 1999, 99 (22) : 2871 - 2875
  • [13] Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
    Barton, M
    Haudenschild, CC
    D'Uscio, LV
    Shaw, S
    Münter, K
    Lüscher, TF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) : 14367 - 14372
  • [14] HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
    Bellosta, S
    Via, D
    Canavesi, M
    Pfister, P
    Fumagalli, R
    Paoletti, R
    Bernini, F
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) : 1671 - 1678
  • [15] Direct vascular effects of HMG-CoA reductase inhibitors
    Bellosta, S
    Bernini, F
    Ferri, N
    Quarato, P
    Canavesi, M
    Arnaboldi, L
    Fumagalli, R
    Paoletti, R
    Corsini, A
    [J]. ATHEROSCLEROSIS, 1998, 137 : S101 - S109
  • [16] Bertolotto A, 1999, ATHEROSCLEROSIS, V143, P455
  • [17] Statins and fibrinogen
    Black, DM
    [J]. LANCET, 1998, 351 (9113) : 1430 - 1430
  • [18] Lovastatin maintains nitric oxide -: but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery
    Brandes, RP
    Behra, A
    Lebherz, C
    Böger, RH
    Bode-Böger, SM
    Mügge, A
    [J]. ATHEROSCLEROSIS, 1999, 142 (01) : 97 - 104
  • [19] COMPARISON OF GEMFIBROZIL VERSUS SIMVASTATIN IN FAMILIAL COMBINED HYPERLIPIDEMIA AND EFFECTS ON APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS, LOW-DENSITY-LIPOPROTEIN SUBFRACTION PROFILE, AND LOW-DENSITY-LIPOPROTEIN OXIDIZABILITY
    BREDIE, SJH
    DEBRUIN, TWA
    DEMACKER, PNM
    KASTELEIN, JJP
    STALENHOEF, AFH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (05) : 348 - 353
  • [20] Brown BG, 1998, AM J CARDIOL, V82, p49T